28 completed, 2 unknown. 30 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 28, Unknown 2 |
| Phase 2 | 1 | Completed 1 |
Follow LG Life Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Pneumococcal conjugate vaccine - Pneumococcal Infections | Phase 1 | Completed | LG Life Sciences | 63 | 2016-09-01 | 2017-06-26 |
| BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone gemigliptin 50mg, rosuvastatin 20mg - Healthy | Phase 1 | Unknown | LG Life Sciences | 37 | 2016-03-01 | 2016-05-11 |
| BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl extended release - Healthy | Phase 1 | Unknown | LG Life Sciences | 25 | 2015-08-01 | 2016-02-02 |
| Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects BEPO-A, REPO-A - Healthy | Phase 1 | Completed | LG Life Sciences | 46 | 2015-04-01 | 2016-03-18 |
| BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl extended release - Healthy | Phase 1 | Completed | LG Life Sciences | 29 | 2014-12-01 | 2015-02-03 |
| Pharmacokinetics and Safety Study of LBAL in Healthy Subjects LBAL, Humira - Healthy Subjects | Phase 1 | Completed | LG Life Sciences | 116 | 2014-08-01 | 2015-06-15 |
| BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone. gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl sustained release - Healthy | Phase 1 | Completed | LG Life Sciences | 24 | 2014-03-01 | 2014-05-08 |
| Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers Gemigliptin - Hepatic Impairment | Phase 1 | Completed | LG Life Sciences | 28 | 2013-09-01 | 2014-07-14 |
| Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects Gemigliptin, Irbesartan - Healthy | Phase 1 | Completed | LG Life Sciences | 30 | 2013-06-01 | 2014-12-30 |
| Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin gemigliptin only, rosuvastatin only, gemigliptin and rosuvastatin - Healthy | Phase 1 | Completed | LG Life Sciences | 30 | 2013-04-01 | 2013-08-28 |
| Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects Gemigliptin and Glimepiride, Glimepiride - Healthy | Phase 1 | Completed | LG Life Sciences | 27 | 2013-02-01 | 2013-04-23 |
| Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets)) - Type 2 Diabetes | Phase 1 | Completed | LG Life Sciences | 24 | 2013-01-01 | 2013-10-24 |
| Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R), Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1), Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1) - Hypertension, Hyperlipidemia | Phase 1 | Completed | LG Life Sciences | 60 | 2012-12-01 | 2013-08-07 |
| Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects LC28-0126, Placebo - Healthy | Phase 1 | Completed | LG Life Sciences | 89 | 2012-12-01 | 2014-03-14 |
| Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel® LBEC0101 (Etanercept 25mg), Enbrel (Etanercept 25mg) - Healthy | Phase 1 | Completed | LG Life Sciences | 48 | 2012-11-01 | 2015-01-30 |
| BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl extended release - Healthy | Phase 1 | Completed | LG Life Sciences | 27 | 2012-10-01 | 2015-04-03 |
| Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1 Erythropoietin - Cerebral Palsy | Phase 1 | Completed | MinYoung Kim, M.D. | 11 | 2012-06-01 | 2014-04-08 |
| Study of LC23-1306 in Healthy Male Subjects LC23-1306, placebo, Ticagrelor - Acute Coronary Syndrome | Phase 1 | Completed | LG Life Sciences | 113 | 2012-03-01 | 2018-08-13 |
| Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R), Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R), Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V) - Hypertension, Hyperlipidemia | Phase 1 | Completed | LG Life Sciences | 30 | 2011-09-01 | 2013-08-08 |
| Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects LC15-0444, Metformin, LC15-0444+Metformin - Healthy | Phase 1 | Completed | LG Life Sciences | 30 | 2011-08-01 | 2011-12-30 |
Showing 20 of 30. Sign in to see all of them.
Hyperlipidemias (2) · Hypertension (2) · Acute Coronary Syndrome (1) · Cerebral Palsy (1) · Communicable Diseases (1) · Diabetes Mellitus, Type 2 (1) · Gout (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hyperuricemia (1) · Pneumococcal Infections (1)
LC15-0444 (11) · Rosuvastatin Calcium (3) · Etanercept (2) · LBEC0101 (2) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (1) · Adalimumab (1) · Erythropoietin (1) · Gemifloxacin (1) · Irbesartan (1) · Ketoconazole (1) · Megestrol Acetate (1) · Metformin (1) · Pioglitazone (1) · Platelet Aggregation Inhibitors (1) · Pneumococcal Vaccines (1)
South Korea (26) · China (1) · Germany (1)
Kyung-Sang Yu, M.D., Ph.D. (3) · Kyung Sang Yu, MD, PhD (2) · Kyung-sang Yu, M.D,Ph.D (2) · Ching-Lung Lai, Dr (1) · Jae-Wook Ko, Professor (1) · Kyun-Seop Bae, M.D., Ph.D. (1) · Kyung-Sang Yu, M.D., Ph.D., M.B.A (1) · Kyung-Sang Yu, MD, PhD (1) · Kyungsoo Park, Ph D, MD (1) · Minyoung Kim, M.D., Ph.D. (1) · Myoung-don Oh, M.D. (1) · Stuart Mair MBChB (1) · Wooseong Huh, Prof (1)
PMID 25350224, PMID 20091678, PMID 22192641, PMID 22534255, PMID 22981147, PMID 24627290, PMID 25450470, PMID 25678778, PMID 27191767, PMID 28551775, PMID 30288156